[The reflection of the dynamics of the serum markers CA l5.3 and CEA in breast cancer].
The aim ao this study was to evaluate the significance of the usual analysis of CA 15.3 test in breast cancer, the efficiency of different therapies (by observing the CA 15.3 dynamics) and to find out the possible connection between CA 15.3 serum level, CEA and the cancer course. By the study of 23 patients diagnosed with breast cancer in various stages, we managed to determine the serum concentration of CA 15.3 and CEA using DELFIA, namely ELISA method, before and after individual therapy. Before therapy, we found pathological CA 15.3 levels in 13 patients (56.5%) and after treatment in 16 patients (69.56%). After individual therapy, we also measured the seric level of CEA, within normal ranges in 3 patients with advanced metastatic disease, who also presented pathological values for CA 15.3. Based on the clinical and experimental data we noticed the connection between pathological values of CA 15.3 and IIA, IIB stages (at significant recurrence risk). The significantly increased levels of CA 15.3 and CEA could be correlated with the locally advanced and metastatic forms.
Cianga
C
C
Catedra de Imunologie, Faculatea de Medicină, Universitatea de Medicină şi Farmacie Gr. T. Popa, Iaşi.
Suliman
I
I
D014408:Biomarkers, Tumor / Q000097:blood*; D001943:Breast Neoplasms / Q000097:blood* / Q000473:pathology; D002272:Carcinoembryonic Antigen / Q000097:blood*; D004797:Enzyme-Linked Immunosorbent Assay / Q000706:statistics & numerical data; D005260:Female; D006801:Humans; D018396:Mucin-1 / Q000097:blood*; D009367:Neoplasm Staging
D014408:Biomarkers, Tumor; D002272:Carcinoembryonic Antigen; D018396:Mucin-1